BioControl Medical, with its subsidiary CerebralRx, has obtained CE Mark approval for use of its FitNeS vagus nerve stimulation system as an adjunct therapy for treatment-resistant depression, which has not responded to four or more antidepressant treatments.

This is the second indication for FitNeS, with the device previously launched for treatment of drug-resistant epilepsy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Featuring an implanted stimulator and stimulation lead, the FitNeS vagus nerve stimulation system delivers low-amplitude stimulation signals to the left vagus nerve in a preferentially directional way towards the brain.

"The INOVATE-HF study enrolment rate continues to exceed expectations, and we are pleased to report that more than 425 patients have been enrolled and 230 implanted with the CardioFit vagal nerve stimulation device."

The FitNeS system effectively activates nerve fibres toward the brain, while minimising the activation of non-related nerve fibres and surrounding tissues. This selective approach has the potential to increase stimulation effectiveness, while minimising risk of side-effects.

BioControl Medical is currently working with its distributors to market the FitNeS system in Europe in the near future for treatment-resistant depression. The FitNeS system is not available in the US.

See Also:

BioControl Medical has also announced that the company is continuing enrolment in the third and final phase of the INOVATE-HF clinical study of its CardioFit system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on the same underlying technology as FitNes, CardioFit system is an implantable electrical stimulation device designed to improve heart function in patients with congestive heart failure.

Washington University in St Louis INOVATE HF steering committee co-chairman Doug Mann said: "The INOVATE-HF study enrolment rate continues to exceed expectations, and we are pleased to report that more than 425 patients have been enrolled and 230 implanted with the CardioFit vagal nerve stimulation device thus far."